A genome-wide screen of Epstein-Barr virus proteins that modulate host SUMOylation identifies a SUMO E3 ligase conserved in herpesviruses

Carlos F. De La Cruz-Herrera, Kathy Shire, Umama Z. Siddiqi, Lori Frappier*

Department of Molecular Genetics, University of Toronto, Toronto, Canada

* lori.frappier@utoronto.ca

Abstract

Many cellular processes pertinent for viral infection are regulated by the addition of small ubiquitin-like modifiers (SUMO) to key regulatory proteins, making SUMOylation an important mechanism by which viruses can commandeer cellular pathways. Epstein-Barr virus (EBV) is a master at manipulating of cellular processes, which enables life-long infection but can also lead to the induction of a variety of EBV-associated cancers. To identify new mechanisms by which EBV proteins alter cells, we screened a library of 51 EBV proteins for global effects on cellular SUMO1 and SUMO2 modifications (SUMOylation), identifying several proteins not previously known to manipulate this pathway. One EBV protein (BRLF1) globally induced the loss of SUMOylated proteins, in a proteasome-dependent manner, as well as the loss of promyelocytic leukemia nuclear bodies. However, unlike its homologue (Rta) in Kaposi’s sarcoma associated herpesvirus, it did not appear to have ubiquitin ligase activity. In addition we identified the EBV SM protein as globally upregulating SUMOylation and showed that this activity was conserved in its homologues in herpes simplex virus 1 (HSV1 UL54/ICP27) and cytomegalovirus (CMV UL69). All three viral homologues were shown to bind SUMO and Ubc9 and to have E3 SUMO ligase activity in a purified system. These are the first SUMO E3 ligases discovered for EBV, HSV1 and CMV. Interestingly the homologues had different specificities for SUMO1 and SUMO2, with SM and UL69 preferentially binding SUMO1 and inducing SUMO1 modifications, and UL54 preferentially binding SUMO2 and inducing SUMO2 modifications. The results provide new insights into the function of this family of conserved herpesvirus proteins, and the conservation of this SUMO E3 ligase activity across diverse herpesviruses suggests the importance of this activity for herpesvirus infections.

Author summary

The functions of many cellular proteins important for anti-viral responses and oncogenesis are controlled by modifications by small ubiquitin-like modifiers (SUMOs). Here we
present the first screen of Epstein-Barr virus (EBV) proteins for those that can globally alter SUMO modifications of cellular proteins. We identify four distinct EBV proteins that increase SUMO modifications and one that decreases them. One of the SUMO upregulating proteins (SM) is conserved in other herpesviruses and we show that this activity is conserved in homologues from herpes simplex virus 1 (HSV1) and cytomegalovirus (CMV). We also show that these three homologues have SUMO E3 ligase activity in in vitro assays and that they bind SUMO and Ubc9, consistent with the expectation of SUMO E3 ligases. The results provide new insights into the functions and mechanisms of action of this family of herpesvirus proteins. Our study identifies the first SUMO E3 ligases for EBV, HSV1 and CMV and provides a new mechanism by which EBV can manipulate cellular processes, through global effects on cellular SUMOylation.

Introduction

The functions of many cellular and viral proteins are controlled by the addition of small ubiquitin-like modifiers (SUMO), in the form of SUMO1 or SUMO2 or SUMO3 chains (referred to as SUMOylation). These modifications can affect protein stability or localization and can promote protein-protein interactions via binding of SUMO to SUMO-interacting sequences (SIMs) [1, 2]. SUMOylation controls many nuclear processes, including genome stability, gene expression, cell cycle progression, senescence and stress and innate immune responses [1, 3–7]. Not surprisingly based on these roles, SUMO signal transduction has been identified as a key factor in the development of several types of cancer; SUMOylation is highly upregulated in many cancers and some cancers have been shown to be dependent on a functioning SUMO system [1, 4].

DNA viruses manipulate many of the cellular processes regulated by SUMOylation and therefore SUMO pathways provide a mechanism to alter these processes. Several different mechanisms have been described by which viral proteins usurp the SUMO system. Cellular SUMOylation involves the SAE1/SAE2 E1 SUMO-activating enzyme, the Ubc9 E2 SUMO-conjugating enzyme and several different SUMO E3 ligases that mediate the interaction of charged Ubc9 with the target protein, facilitating the SUMO transfer [2]. Some viral proteins globally alter SUMOylation by hijacking Ubc9 [8]. For example, the E6 protein of human papillomavirus (HPV) type 16/18 lowers Ubc9 levels thereby globally decreasing SUMOylation [9]. Some viruses upregulate SUMOylation by encoding E3 SUMO ligases that function in conjunction with Ubc9. Two adenovirus proteins have been reported to have SUMO ligase activity; adenovirus E1B-55K induces SUMO1 modification of p53 [10, 11], while adenovirus E4-ORF3 induces SUMO3 modification of the transcription intermediary factor 1γ (TIF-1γ) [12]. In addition, the K-bZIP protein of Kaposi’s sarcoma-associated herpesvirus (KSHV) was found to be a SUMO2/3-specific E3 ligase that modifies itself as well as p53 and Rb [13].

Viruses can also downregulate SUMOylation by encoding SUMO-specific proteases (SENPs) or SUMO-targeted ubiquitin ligases (STUbLs); the latter which ubiquitylates SUMO-modified proteins leading to their degradation. Both human adenoviruses and vaccinia virus encode a SENP [14]. In addition, two distinct viral STUbLs have been identified; the ICP0 protein of herpes simplex virus 1 (HSV-1) and its homologue (ORF61) in varicella zoster virus, and the unrelated Rta protein of KSHV and its homologue in murine gammaherpesvirus 68 [15–19]. Like the cellular STUbL RNF4 [20], a major target of degradation of the viral STUbLs are promyelocytic leukemia (PML) and associated proteins since they are highly SUMO-modified [15, 16, 21]. Since PML nuclear bodies are part of the innate immune response that senses
herpesvirus genomes and suppresses their lytic infection, these STUbLs have important roles in promoting lytic infection [16, 22, 23].

EBV is a widespread herpes virus that is a causative agent of several types of cancer, including Burkitt's lymphoma, nasopharyngeal carcinoma and 10% of gastric carcinoma [24–26]. Life-long infection occurs due to the ability of EBV to alternate between latent modes of infection, with restricted viral gene expression, and lytic infection involving expression of an additional ~70 viral proteins. Together, these lytic proteins manipulate many cellular processes including innate immune responses, cell cycle progression and DNA damage responses, in order to promote cell survival and virion production [27, 28]. However, the functions of many EBV lytic proteins are unknown and even proteins with an assigned function may have additional unidentified roles. Given the importance of SUMO pathways in oncogenesis and cellular processes manipulated by EBV, it seems likely that some EBV proteins may function by targeting SUMO pathways.

Little is currently known about the interplay between EBV and SUMO systems. To date only one EBV protein, the latent membrane protein 1 (LMP1), has been shown to act directly on SUMOylation. LMP1 binds to Ubc9 and upregulates its activity, resulting in increased SUMOylation in EBV latent infection [29, 30]. This includes SUMOylation of KRAB-associated protein 1 (KAP1), which promotes its repression of the lytic immediate early promoters and lytic replication origin, thereby promoting latency [31]. In lytic infection, SUMO2/3 conjugates have been found to accumulate late in infection, which in part may be due to expression of a viral miRNA that downregulates RNF4 [32]. Presently no SUMO ligases, SENPs or STUbLs have been identified for EBV.

To investigate how EBV proteins impact cellular pathways, we previously generated an expression library for most of the EBV lytic proteins, and used the C-terminal FLAG tag on each protein to determine their subcellular localization [33]. These EBV proteins were then screened for the ability to disrupt or alter PML nuclear bodies [33], contribute to cell cycle arrest at the G1/S interface [28] and inhibit the cellular DNA damage response [34]; characteristics typical of EBV lytic infection. These screens have led to new functions for several EBV proteins demonstrating the utility of the approach. Here we screened the library of EBV proteins for those that globally affect cellular SUMO1 and SUMO2 modifications and identified a few EBV proteins that upregulate SUMOylation and one that downregulates SUMOylation. The downregulator is the Rta homologue of the KSHV and gammaherpesvirus 68 (γHV68) STUbLs, suggesting a conserved role for these protein in decreasing SUMOylation. We show that one of the SUMO upregulators (SM) has characteristics of a SUMO E3 ligase and that this activity is conserved in SM homologues in HSV1 (UL54/ICP27) and human cytomegalovirus (CMV; UL69), identifying the first SUMO E3 ligase for any of these herpesviruses.

Results
Identification of EBV proteins that globally affect cellular SUMOylation

To identify EBV proteins that hijack cellular SUMOylation, we screened a library of 51 EBV lytic proteins for the ability to globally affect SUMO1 and SUMO2 modifications upon overexpression. Such a screen can identify proteins with intrinsic SUMOylation or SUMO degradation activities or that have prominent interactions with SUMO pathway proteins [15, 35–37]. Initial screens were performed in both 293T cells transiently expressing His6-tagged SUMO1 or SUMO2 and in HeLa cells containing integrated copies of His6-SUMO1 or His6-SUMO2 that express these proteins at close to endogenous levels [38]. In both cases, FLAG-tagged EBV proteins were expressed by transient transfection and, 36 hrs later, His-tagged proteins were recovered from cell lysates on metal chelating resin under denaturing conditions. Western
blots were then performed using SUMO1 or SUMO2 antibodies to detect all proteins covalently modified by His-SUMO. The SUMOylation profile in the presence of each viral protein was compared to that with empty FLAG-tagged plasmid. In addition, we used the EBV LMP1 protein as a positive control for global upregulation of SUMOylation and the HSV1 ICP0 protein as a positive control for global downregulation of SUMOylated proteins. Examples of these controls and selected EBV proteins are shown in Fig 1 (see S1 Fig for confirmation of ICP0 and LMP1 expression). The up or down regulation of global SUMOylation was assessed by comparing the intensity of the ladder of SUMOylated proteins in the presence of the EBV protein to that of the empty plasmid, and results for all 51 EBV proteins in the two cell systems are summarized in Table 1 (with the degree of the effect indicated by the number of + signs for upregulation or – signs for downregulation). For proteins that appeared to affect global SUMOylation in 293T and HeLa cells, assays with transient expression of His6-SUMO1 or His6-SUMO2 were repeated in a nasopharyngeal carcinoma cell line (CNE2Z) relevant for EBV infection (Fig 1C and Table 1). We then looked for EBV proteins that consistently up or down regulated SUMO1 or SUMO2 modifications in all three cell systems. Six EBV proteins met this criteria and had moderate to high effects in at least one cell system (marked in grey in Table 1). Five of these increased SUMOylation while one (BRLF1 or Rta) decreased SUMOylation. Quantification of these effects is shown in Table 2. Ability to modulate SUMOylation did not correspond to the expression levels of the viral proteins, as BMLF1 and BRLF1 were expressed at relatively low levels and some highly expressed proteins (such as BXLF1) did not affect SUMOylation. In addition, increases in SUMOylation was not simply due to SUMOylation of the viral protein itself, as even when SUMOylation of the viral protein could be detected, it resulted in only a few discreet bands and not the high molecular weight smears seen in the SUMOylation screen (see examples in S2 Fig). Upregulation of SUMOylation by BGLF2, BMRF1 and SM and down regulation of SUMOylation by Rta was also confirmed by detecting endogenous SUMO levels in 293T cells (Fig 2).

**SUMO-associated properties of BRLF1**

BRLF1 was the only EBV protein that we found to consistently decrease the level of SUMOylated proteins with a moderate to high effect. This decrease was seen for both SUMO1- and SUMO2-modified proteins. This effect was further verified by expressing BRLF1 in 293T cells and blotting for endogenous SUMO (Fig 2). The observed decrease in SUMO1 and SUMO2 modified proteins was not due to effects on SUMO or Ubc9 transcripts, as the level of SUMO1, SUMO2 or Ubc9 mRNA was not significantly changed by Rta expression (S3 Fig). Since the KSHV homologue of BRLF1 (Rta) was shown to be a STUbL, we asked whether BRLF1 had characteristics consistent with a STUbL. Since STUbLs target SUMOylated proteins for proteasomal degradation, we asked whether the loss of SUMOylated proteins induced by BRLF1 could be restored by blocking the proteasome with MG132. As shown in Fig 3A, MG132 at least partly countered the loss of both SUMO1 and SUMO2-modified proteins that is induced by BRLF1, mirroring the results with the HSV1 STUbL, ICP0. Since BRLF1 has been reported to associate with the cellular STUbL, RNF4 [39], we also asked whether the loss of SUMOylated proteins caused by BRLF1 required RNF4. However, much like ICP0, BRLF1 was found to induce the loss of both SUMO1 and SUMO2-modified proteins in CNE2Z cells (relative to empty vector control) regardless of whether or not RNF4 was silenced (Fig 3B).

Rta proteins from KSHV and γHV68 have ubiquitin ligase activity that can be observed by upregulation of global cellular ubiquitylation upon their overexpression [15, 18, 40]. To determine if this was also true for BRLF1, we expressed it along with His6-myc-ubiquitin in both 293T and CNE2Z cells, with and without MG132 treatment, then recovered ubiquitylated
proteins on metal chelating resin and detected them by Western blotting with anti-myc antibody (Fig 3C). While KSHV Rta and HSV1 ICP0 induced ubiquitylation in both cell lines both with and (to a lesser degree) without MG132, no induction of ubiquitylation was detected with BRLF1. This suggests that, unlike Rta and ICP0, BRLF1 induces the loss of SUMOylated proteins without endogenous ubiquitin ligase activity.

We next asked whether BRLF1 could bind SUMO. To this end, FLAG-BRFL1 was purified from 293T cells on anti-FLAG resin under high salt conditions (to limit protein interactions) and extensively washed (Fig 4A, left panel; BRLF1). Negative control resin was similarly generated using lysates from 293T cells with empty FLAG vector (Fig 4A, left panel; EV). GST-SUMO1, GST-SUMO2 or GST alone were generated in Ecoli (Fig 4A, left panel) and equal amounts were applied to negative control or BRLF1-containing resin followed by extensive washing. Resin containing BRLF1, but not empty vector, retained GST-SUMO1 and GST-SUMO2 but not GST alone (Fig 4A, right panel), showing that BRLF1 can bind SUMO1 and SUMO2.

Since PML proteins are highly SUMO-modified, they are often a target of proteins that bind SUMO and disrupt/degrade SUMOylated proteins [15, 41–43]. Interestingly our previous screen of over 200 EBV, HSV1 and CMV proteins for ability to induce loss of PML NBs in U2OS cells identified BRLF1 as one of the top hits [33]. We further verified this property by examining the effect of BRLF1 on PML nuclear bodies and proteins in CNE2Z nasopharyngeal carcinoma cells (Fig 4B and 4C). BRLF1 consistently decreased the number and intensity of PML nuclear bodies and the level of PML proteins (although not as dramatically as ICP0 which is known to have multiple mechanisms of targeting PML [44]). The results are consistent with the ability of BRLF1 to induce the loss of SUMO-modified proteins.

SUMO induction activity of SM is conserved in homologues in other herpesviruses

Two of the proteins that upregulated SUMOylation in our screens, BMLF1 and SM (also called EB2) share common sequences, as BMLF1 is the C-terminal part of SM (Table 1, Fig 2, Fig 5). We focused our studies on SM since it is the functional protein. In assays in 293T cells detecting endogenous SUMO levels, SM expression was found to induce SUMO1 modifications without a noticeable effect on SUMO2 modifications (Fig 2). This was consistent with what we observed in the initial screen, where SUMO1 modifications were more obviously upregulated than SUMO2 modifications (Table 1). Interestingly, SM itself was efficiently modified by SUMO2 and less obviously by SUMO1 (S1 Fig). SM is known to have several roles in lytic EBV infection, including EBV mRNA export, splicing activation and transcriptional activation [45–49]. SM is conserved in all herpesviruses and its homologues in HSV1 (UL54 or ICP27) and CMV (UL69) have similar roles as SM in lytic infection [50, 51]. We reasoned that if SUMO induction by SM was important for viral infection, then this property would be conserved in the SM homologues in other herpesviruses. Therefore we compared the abilities of SM, UL54 and UL69 to induce SUMO1 and SUMO2 modifications in all three cell systems used for the initial screen (Fig 5). SM and UL69 were consistently found to upregulate SUMO1
Table 1. Screen of EBV Lytic proteins for global effects on cellular SUMOylation.

| Protein | Function | 293T | 293T | HeLa | HeLa | CNE2Z | CNE2Z |
|---------|----------|------|------|------|------|-------|-------|
| BALF1   | bcl-2 homolog | n/e  | +    | n/e  | +    | n/e   | +     |
| BALF2   | ssDNA binding protein | n/e  | n/e  | n/e  | +    | n/e   |
| BALF3   | Endonuclease; DNA packaging | n/e  | n/e  | n/e  | n/e  |
| BARF1   | secreted cell stimulatory factor | n/e  | n/e  | n/e  | n/e  |
| Balf1   | ribonucleotide reductase small subunit | n/e  | n/e  | n/e  | n/e  |
| BBLF1   | Myristylated membrane protein | +    | n/e  | n/e  | n/e  |
| BBLF2   | part of BBLF2/3 protein | +    | +    | n/e  | n/e  | n/e   | +     |
| BBLF4   | DNA helicase | n/e  | n/e  | n/e  | +    | n/e   |
| BBRF1   | portal protein | n/e  | +    | n/e  | +    | n/e   | n/e   |
| BBRF2   | uncharacterized HSV1 UL7 homologue | n/e  | n/e  | n/e  | n/e  |
| BcBF1   | TATT binding protein; late gene activator | n/e  | n/e  | n/e  | n/e  |
| BCRF1   | viral Interleukin 10 | n/e  | -    | n/e  | -    | n/e   |
| BDLF1   | minor capsid protein | n/e  | n/e  | n/e  | n/e  |
| BDLF2   | glycosylated envelope protein | n/e  | n/e  | n/e  | n/e  |
| BDLF3   | envelope glycoprotein gp150 | n/e  | +    | n/e  | n/e  | +    | n/e   |
| BDLF4   | late gene expression | +    | n/e  | n/e  | n/e  | +    | -     |
| BDRF1   | scaffold protein | n/e  | +    | n/e  | +    | n/e   | n/e   |
| BFLF2   | DNA packaging | n/e  | n/e  | n/e  | n/e  |
| BFRF1   | viral egress | n/e  | n/e  | n/e  | n/e  |
| BFRF2   | uncharacterized HSV1 UL49 homologue | n/e  | n/e  | n/e  | n/e  |
| BFRF3   | small capsid protein | n/e  | n/e  | n/e  | n/e  |
| BGLF1   | DNA packaging; HSV1 UL17 homologue | n/e  | n/e  | n/e  | n/e  |
| BGLF2   | cell cycle & AP-1 modulator | +++  | ++   | ++   | ++   | ++    |
| BGLF3   | serine threonine kinase | n/e  | n/e  | n/e  | n/e  |
| BGLF4   | uncharacterized HSV1 UL15 homologue | n/e  | n/e  | n/e  | +    |
| BGRF1   | uracil DNA glycosylase | +    | n/e  | n/e  | n/e  | +    | n/e   |
| BKRF3   | scaffold protein | n/e  | n/e  | n/e  | n/e  |
| BKRF4   | Histone binding protein | +    | n/e  | n/e  | +    |
| BLLF2   | uncharacterized late gene | n/e  | n/e  | n/e  | n/e  |
| BLLF3   | dUTPase | +    | n/e  | n/e  | n/e  |
| BLRF1   | envelope glycoprotein, gN homologue | n/e  | n/e  | n/e  | n/e  |
| BLRF2   | uncharacterized tegument | n/e  | n/e  | n/e  | n/e  |
| BMLF1   | C-terminal part of SM/EB2 | +++  | +    | n/e  | ++   | ++    |
| BMRF1   | DNA polymerase processivity factor | ++++ | ++   | ++   | ++   | ++    |
| BNLF2a  | immune evasion; TAP inhibitor | n/e  | n/e  | n/e  | n/e  | n/e   |
| BNLF2b  | uncharacterized | n/e  | n/e  | n/e  | n/e  |
| BORF1   | minor capsid protein | n/e  | n/e  | n/e  | n/e  |
| BORF2   | Ribonucleotide-reductase, large subunit | n/e  | +    | n/e  | n/e  |
| BRLF1   | Rta transcriptional activator | -    | -    | -    | -    |
| BRRF1   | Na transcriptional activator | +    | n/e  | -    | n/e  |
| BRRF2   | viral egress | +    | n/e  | n/e  | n/e  | +    | n/e   |
| BSLF1   | DNA Primase | n/e  | n/e  | n/e  | n/e  |
| BSLF2   | N-terminal part of SM/EB2 | +    | n/e  | n/e  | +    | ++    |
| BSRF1   | uncharacterized tegument protein | n/e  | n/e  | n/e  | n/e  |
| BTRF1   | uncharacterized | n/e  | n/e  | n/e  | n/e  |
| BVL1.5  | uncharacterized | n/e  | n/e  | n/e  | n/e  |

(Continued)
modifications in all three cell lines, with little to no effect on SUMO2 modifications. Conversely, UL54 consistently increased SUMO2 modifications with little to no effect on SUMO1 modifications. Quantification from three independent experiments in each cell line is shown in Table 2. These effects were not due to induction of SUMO or Ubc9 transcripts as neither SUMO1, SUMO2 nor Ubc9 mRNA levels were significantly affected by SM, UL54 or UL69 (S3 Fig). Since HSV1, CMV and EBV represent the three different subfamilies of herpesviruses (alpha, beta and gamma respectively), the results indicate that global induction of SUMOylation is an activity that is conserved in the SM family of proteins, although different family members have different specificities for SUMO1 vs SUMO2.

SM, UL54 and UL69 bind SUMO and Ubc9
Proteins that directly affect SUMOylation typically bind to SUMO and/or the Ubc9 E2 SUMO-conjugating enzyme. Therefore to determine whether SM, UL54 and UL69 are acting directly on cellular SUMOylation, we first examined their association with SUMO1, SUMO2 and Ubc9 in human cells. To this end, HeLa cells containing integrated copies of His6-SUMO1 or His6-SUMO2 were transfected with FLAG-tagged SM, UL54 or UL69 followed by recovery of the His6-SUMOs on metal chelating resin under native conditions (Fig 6A and 6B). All three viral proteins were pulled down by SUMO1 and SUMO2 to varying degrees indicating

Table 1. (Continued)

| Protein   | Function                              | 293T  | HeLa | CNE2Z |
|-----------|---------------------------------------|-------|------|-------|
|           |                                       | S1    | S2   | S1    | S2   | S1    | S2   |
| BVRF1     | uncharacterized tegument protein      | +     | n/e  | n/e   | n/e  | +     |      |
| BVRF2     | autocatalytic scaffold protease       | ++    | ++   | ++    | n/e  | ++    |      |
| BKLF1     | Thymidine kinase                      | n/e   | n/e  | n/e   | ++   | n/e   | +    |
| BZLF1     | Zta (ZEBRA) transcriptional activator | n/e   | n/e  | n/e   | n/e  | n/e   |      |
| SM (EB2)  | mRNA binding and export               | +++   | n/e  | +     | n/e  | +++   | n/e  |

* EBV proteins that induce (+) or decrease (-) SUMO1 (S1) and SUMO2 (S2) modifications are indicated for three cell lines. The number of + or - indicates the degree of the effect. n/e = no effect. Proteins that gave consistent effects in all three cell lines with at least one moderate (++) or higher effect are marked in grey.

https://doi.org/10.1371/journal.ppat.1007176.t001

Table 2. Fold change in global SUMOylation relative to empty vector control.

| Protein | SUMO1 | SUMO2 | SUMO1 | SUMO2 | SUMO1 | SUMO2 |
|---------|-------|-------|-------|-------|-------|-------|
| 293T    |       |       |       |       |       |       |
| LMP1    | 4.63 ± 0.19 | 1.70 ± 0.16 | 2.01 ± 0.44 | 1.73 ± 0.05 | 2.25 ± 0.89 | 2.08 ± 0.95 |
| ICP0    | 0.29 ± 0.12 | 0.26 ± 0.20 | 0.75 ± 0.05 | 0.74 ± 0.04 | 0.56 ± 0.07 | 0.17 ± 0.04 |
| BGLF2   | 3.84 ± 0.69 | 2.0 ± 0.39 | 1.93 ± 0.73 | 1.65 ± 0.01 | 1.61 ± 0.28 | 1.91 ± 0.41 |
| BMLF1   | 2.75 ± 0.46 | 1.26 ± 0.03 | 1.11 ± 0.09 | 1.56 ± 0.29 | 1.48 ± 0.07 | 1.76 ± 0.45 |
| BMRF1   | 3.02 ± 0.03 | 1.74 ± 0.40 | 2.57 ± 0.12 | 1.65 ± 0.05 | 1.83 ± 0.57 | 2.07 ± 0.74 |
| BRLF1   | 0.45 ± 0.47 | 0.54 ± 0.07 | 0.61 ± 0.03 | 0.65 ± 0.04 | 0.59 ± 0.08 | 0.73 ± 0.29 |
| BVRF2   | 1.98 ± 0.08 | 1.98 ± 0.24 | 1.33 ± 0.21 | 1.58 ± 0.30 | 1.05 ± 0.06 | 1.71 ± 0.29 |
| SM      | 4.52 ± 1.56 | 1.07 ± 0.45 | 1.80 ± 0.46 | 1.15 ± 0.10 | 2.62 ± 0.46 | 1.02 ± 0.29 |
| UL54    | 1.15 ± 0.46 | 1.40 ± 0.19 | 1.02 ± 0.06 | 1.96 ± 0.17 | 1.24 ± 0.22 | 2.27 ± 0.13 |
| UL69    | 2.48 ± 0.21 | 1.06 ± 0.46 | 1.50 ± 0.16 | 1.26 ± 0.25 | 2.0 ± 0.17 | 0.99 ± 0.37 |

* Average values from multiple experiments are shown +/- standard deviation.

https://doi.org/10.1371/journal.ppat.1007176.t002
that they interact with SUMO. However, SM and UL69 were more efficiently recovered with SUMO1 than UL54 (Fig 6A), and UL54 was more efficiently recovered with SUMO2 than SM and UL69 (Fig 6B). This specificity reflects the ability of these proteins to induce SUMO1 vs
SUMO2 modifications, suggesting that the degree of SUMO binding influences their SUMOylation induction specificity.

To further investigate the SUMO specificities of the viral proteins and determine if SUMOs are bound directly, we expressed and partially purified FLAG-tagged SM, UL54 and UL69.

https://doi.org/10.1371/journal.ppat.1007176.g003

**Fig 3.** BRLF1 induces proteasomal-dependent loss of SUMOylated proteins without inducing ubiquitylation. A. 293T cells were transfected with plasmids expressing ICP0, FLAG-BRLF1 or empty vector (EV) control, then treated with MG132 (+) or left untreated (-). 34 hours post-transfection, cell lysates were analysed by Western blotting using the antibodies against SUMO1, SUMO2, ICP0, FLAG (BRLF1) or actin. Samples for SUMO1 and SUMO2 blots were run on separate gels and the actin loading control is shown for each. B. Experiments in A (without MG132) were repeated in CNE2Z cells with (siRNF4) and without (Control) silencing of RNF4. C. 293T (left) or CNE2Z (right) cells were transfected with plasmids expressing either ICP0, FLAG-BRLF1, Strep-Rta or empty vector (EV) along with a plasmid expressing myc-his-ubiquitin. Cell lysates were Western blotted directly (input) with antibodies against myc (to detect ubiquitin conjugates), FLAG (for BRLF1), Strep (for Rta) or ICP0. Myc-his-ubiquitin containing proteins were isolated from the lysates on metal chelating resin (Pulldown) prior to blotting for myc.
from *E. coli* (Fig 7A) and used it in GST pull down assays with GST-tagged SUMO1 or SUMO2 (also generated in *E. coli*). All three viral proteins were retained on glutathione resin by GST-SUMO1 and GST-SUMO2 but not by GST alone (Fig 7B). However, once again the SUMO specificities varied among the viral proteins, with SM and UL69 being more efficiently bound by SUMO1 than SUMO2, and UL54 being more efficiently bound by SUMO2 than SUMO1. The results suggest that the ability to directly bind SUMO is an important factor in SUMOylation induction in cells.

---

**Fig 4. BRLF1 binds SUMO and induces loss of PML proteins and nuclear bodies.** A. BRLF1-FLAG was purified from 293T cell lysate on anti-FLAG resin. Control resin loaded with the same 293T lysate lacking BRLF1 was generated as a control (EV). Resins were then incubated with *E. coli* extract containing equal amounts of GST, GST-SUMO1 or GST-SUMO2, washed and eluted in SDS buffer (FLAG pulldowns). The Coomassie gel on the left shows the BRLF1-FLAG and GST proteins used in the assay (arrowheads indicating full length proteins). The GST Western blot on the right shows the recovery of GST and GST-SUMOs. B. CNE2Z cells were transfected with plasmids expressing FLAG-tagged BRLF1, then, 24 hours later, fixed and stained for FLAG and PML. The number of PML NBs were counted in 50 FLAG-positive and 50 FLAG-negative cells on the same slide in two independent experiments, and average values are shown on the bar graph. The effect of ICP0 expression on the number of PML NBs in the CNE2Z cells is also shown on the graph as a positive control. p values (** = 0.001 < P < 0.01; *** = P < 0.001) are shown. C. CNE2Z cells were transfected with plasmids expressing FLAG-tagged BRLF1, ICP0 or empty FLAG vector. 48 hours later, cells were lysed and immunoblotted for PML, ICP0, FLAG (BRLF1) and actin.
Fig 5. Effect of SM, UL54 and UL69 on global SUMO1 and SUMO2 modifications. 293T (A) and CNE2Z (C) cells were co-transfected with plasmids expressing His6-SUMO1 (left panels) or His6-SUMO2 (right panels) and either ICP0, LMP1, FLAG-SM, FLAG-UL54, FLAG-UL69 or empty vector.
We also asked whether SM, UL54 and UL69 interact with the E2 enzyme for SUMOylation, Ubc9. Immunoprecipitation of endogenous Ubc9 from 293T cells expressing SM, UL54 or UL69 showed that all three viral proteins were associated with Ubc9 (Fig 6C). We examined whether these associations were direct by using the E.coli purified viral proteins in GST pull down assays with GST-Ubc9 (Fig 7B). SM, UL54 and UL69 were all retained on glutathione resin by GST-Ubc9 but not by GST alone, showing that each can directly bind Ubc9.

**SM, UL54 and UL69 have E3 SUMO ligase activity in vitro**

The properties of SM, UL54 and UL69 in inducing global SUMOylation, binding directly to SUMO and binding directly to Ubc9 are consistent with SUMO E3 ligases. Therefore we investigated whether these viral proteins have SUMO E3 ligase activity in a purified *in vitro* system with the SUMO E1 (SAE) and E2 (Ubc9) enzymes, SUMO1 or SUMO2 and full length monomeric p53 as a substrate [52]. p53 was used as it is a well characterized substrate for SUMOylation that has previously been shown to require E3 ligases *in vitro* [10, 11, 13, 53]. All of the proteins in this assay (SAE, Ubc9, SUMO1, SUMO2, p53 and the viral proteins) were generated in E.coli to ensure that no contaminating SUMO E3 ligases are present. The addition of

![Fig 6. SM, UL54 and UL69 interact with SUMO1, SUMO2 and Ubc9 in human cells. A and B. HeLa cells containing integrated His6-SUMO1 (A) or His6-SUMO2 (B) were transfected with plasmids expressing FLAG-SM, FLAG-UL54, FLAG-UL69 or empty vector (pCMV). 36 hours later, His6-SUMO was recovered from cell lysates on metal chelating resin under nondenaturin conditions and immunoblotted for His and FLAG (left panels). 5% of the input lysate was also immunoblotted for His and FLAG (right panels). C. 293T cells were transfected with plasmids expressing FLAG-SM, FLAG-UL54, FLAG-UL69 or empty vector (pCMV). 36 hours later, immunoprecipitations were performed for endogenous Ubc9, followed by immunoblots with Ubc9 and FLAG antibody (left panels). Immunoblots were also performed on 5% of the input lysates (right panels). For all experiments, longer exposures were used for pulldowns/IPs than for inputs in order to provide optimum exposures to show differences between recoveries of different viral proteins in pulldowns and even levels of the viral proteins in inputs.

https://doi.org/10.1371/journal.ppat.1007176.g006
increasing amounts of purified SM (Fig 8A), UL54 (Fig 8B) or UL69 (Fig 8C) resulted in titratable induction of a shifted form of p53 consistent with mono-SUMOylated p53 (top panels). This shift was seen with both SUMO1 (left panels) and SUMO2 (right panels). Western blots for SUMO1 or SUMO2 confirmed that the shifted band was SUMO-modified p53 (middle panels). This band was not seen in assays using the highest amounts of the viral proteins in the absence of SAE, confirming that this SUMOylation was dependent on the E1 SUMO conjugating enzyme. Together the results indicate that SM, UL54 and UL69 can act as SUMO E3 ligases.

SM, UL54 and UL69 can induce p53 SUMOylation in human cells

Since we have shown that SM, UL54 and UL69 can all catalyze p53 SUMOylation in vitro, we investigated whether they also induced p53 SUMOylation in cells. To this end, 293T cells were co-transfected with constructs expression His6-SUMO1 or His6-SUMO2 and FLAG-tagged SM, UL54 or UL69. His-tagged proteins were then recovered on metal chelating resin under denaturing conditions and analysed by Western blotting using anti-p53 antibody. All three viral proteins were found to induce mono-SUMOylation of endogenous p53, to a similar degree as the LMP1 positive control (Fig 9A). UL54 induced less SUMO1-modification of p53 than SM and UL69, consistent with the trend we observed for global SUMOylation. In SUMO2 experiments (Fig 9B), while the mono-SUMO2 p53 band (~70 KDa) was not obviously affected by SM, UL54 or UL69 as compared to the empty vector control, higher molecular weight SUMO2 products were evident with UL54 (and the LMP1 positive control). Together the results suggest that SM, UL54 and UL69 can all affect p53 SUMOylation, but with different SUMO1 vs SUMO2 specificities that reflect their effects on global SUMOylation and SUMO binding.
Effect of SM depletion on SUMO1 profiles in EBV infection

The fact that several EBV proteins can affect SUMOylation suggests a complicated interplay with SUMO pathways during EBV infection which would be best understood after identifying the specific targets of each of the EBV proteins. However, to begin to explore the effect of SM on SUMOylation in the context of EBV infection, we examined the cellular SUMO1 profile in EBV-positive gastric carcinoma cells (AGS-EBV) after lytic reactivation with and without SM depletion with SM-targeted siRNA. Quantification of SM transcripts showed that this gene was expressed by 16 hours post-reactivation and continued to increase in levels at 24 and 48

![Figure 8. In vitro SUMO E3 ligase assays.](https://doi.org/10.1371/journal.ppat.1007176.g008)

In vitro SUMOylation assays were performed using Abcam SUMOylation Assay Kit with SUMO1 (left panels) or SUMO2 (right panels) and E.coli purified full length p53 as a substrate. Various amounts of His6-SM-3FLAG (A), His6-UL54-3FLAG (B) and His6-UL69-3FLAG (C), generated as in Fig 7A, were added to the indicated reactions where 1x is estimated to be 100 ng of full length protein. Negative controls lacking SAE are also shown. All lanes contained equal amounts of p53 substrate, SUMO and Ubc9. After 1.5 hrs reactions, Western blots were performed with antibodies against p53, SUMO1 (left panels), SUMO2 (right panels) and FLAG (to detect SM, UL54, UL69). The position of SUMO-modified p53 is indicated by the arrowheads.
hour time points (Fig 10A). Pre-treatment with SM siRNA significantly decreased SM levels, particularly at 24 and 48 hour time points (Fig 10A). At the same time points, cell lysates were collected and analysed for SUMO1 profiles by Western blotting (Fig 10B).

Fig 9. Induction of p53 SUMOylation by SM, UL54 and UL69 in cells. 293T cells were co-transfected with plasmids expressing His6-SUMO1 (A) or His6-SUMO2 (B) and plasmids expressing LMP1, ICP0, FLAG- SM, FLAG-UL54 or FLAG-UL69 or empty vector. His6-tagged proteins were recovered on metal chelating resin under denaturing conditions and immunoblotted for p53. Samples of the lysates (Input) were also immunoblotted for p53 and FLAG. Positions of SUMO1- or SUMO2-modified p53 are indicated.

https://doi.org/10.1371/journal.ppat.1007176.g009

Fig 10. Silencing of SM in EBV lytic infection decreases some SUMO1 modifications. AGS-EBV cells were treated with siRNA against SM or negative control siRNA, then reactivated to the lytic cycle for the indicated times. A. SM mRNA was quantified by qRT-PCR. B. Cell lysates were analysed by Western blotting with antibodies against SUMO1 and actin (left panel). Pertinent time points were rerun with additional sample (right panel).

https://doi.org/10.1371/journal.ppat.1007176.g010
SUMO1-containing bands migrating at ~62 and 68 Kda were observed during the early stages of lytic infection but not at 48 hrs post induction (at which time greatly increased SUMO1 profiles suggest a stress response). These bands were reduced with SM depletion, most obviously at 24 hours post-induction when SM is accumulating in the cells. Note that these bands are too small to be any SUMO1-modified version of SM, which would migrate above the 72 Kda marker (although S2 Fig suggests there would be little SUMO1-modified SM). The results support the ability of SM to affect SUMOylation of some proteins in the context of EBV infection.

Discussion
EBV manipulates many cellular pathways in order to promote infection and avoid host immune responses, and under some circumstances such alterations can lead to oncogenesis. Here we show that some EBV proteins can dramatically affect the SUMOylation of host proteins, providing an additional mechanism by which EBV can manipulate cells. We identified one EBV protein (BRLF1/Rta) that decreases the level of SUMOylated proteins and four distinct proteins that increase SUMOylated proteins. One of the latter proteins (SM) has characteristics of a SUMO E3 ligase, and this activity is conserved in SM homologues in HSV1 (UL54) and CMV (UL69) suggesting the importance of this activity for herpesvirus infections.

Our screen using overexpressed EBV proteins was designed so that viral proteins with the ability to affect SUMO pathways would manifest as a global SUMOylation phenotype, even though in the context of infection they may only affect a subset of SUMOylated proteins. Herpesviruses in lytic infection modulate a wide variety of cellular processes that involve SUMOylation, the best studied being the disruption of PML NBs by viral SUMO-targeted ubiquitin ligases that degrade PML proteins or SUMO-interacting proteins that disrupt PML protein interactions [15, 19, 54–57]. Indeed, the SUMO downregulator that we identified here (BRLF1) was also shown to disrupt PML NBs. Additional SUMO-regulated processes controlled by herpesviruses include interference with cell cycle progression, resulting in G1/S arrest, and inhibition of DNA damage responses [58–64]. Our previous screens have identified BGLF2 and BMRF1 as contributing to G1/S arrest [28] and BMRF1 as an inhibitor of DNA damage response [65]. We do not yet know the mechanism of these effects, but the fact that both proteins were found to upregulate SUMOylation suggests that they may be affecting cell cycle progression and the DDR by increasing SUMOylation of some cellular proteins.

The only EBV protein that we found to globally decrease SUMOylation was BRLF1 (also called Rta); an immediate early protein conserved in γ-herpesviruses and known to function as a transcriptional activator. Interestingly, the BRLF1 homologues (Rta) in KSHV and murine γHV68 were both shown to have ubiquitin ligase activity [18, 40] and KSHV Rta was later shown to be a SUMO-targeted ubiquitin ligase (STUbL) [15]. Like these Rta proteins, the protein loss we observed with BRLF1 was proteasomal dependent, suggesting that induction of protein degradation is a conserved function of the Rta proteins. While the ability of γHV68 Rta to bind SUMO has not been reported, it is known to degrade the RelA subunit of NF-κB which is highly SUMO-modified by PIAS3, raising the possibility that SUMOylation of RelA is part of the targeting mechanism by Rta [18, 66]. KSHV Rta was shown to contain SUMO-interacting motifs that bind SUMO and to induce degradation of the highly SUMOylated PML proteins [15]. In addition, the STUbL activity of KSHV Rta was shown to be required for transcriptional activation, suggesting that removal of suppressive SUMOylated proteins promotes transcription [15]. Similarly, we found that EBV Rta binds SUMO and induces loss of PML NBs and proteins ([33] and Fig 4). In addition, EBV Rta is SUMO modified and this modification has been found to increase its transactivation activity [33, 67, 68]. However, despite the many similarities between KSHV and EBV Rta, we could not find evidence of
ubiquitin ligase activity in EBV Rta, even though this activity was readily apparent in the same assay with KSHV Rta (Fig 3C). This is likely due to the low sequence conservation between these proteins, including the lack of catalytic cysteines which are conserved in KSHV and γHV68 Rta [18]. Interestingly, a KSHV Rta mutant lacking ubiquitin ligase activity still induces the degradation of PML proteins suggesting that it has two mechanisms of degrading SUMOylated proteins [15]. This second (unknown) mechanism of degradation of SUMOylated proteins may be conserved in EBV Rta.

Our screen identified four distinct EBV proteins that globally upregulated SUMOylation. (SM, BGLF2, BMRF1, BVRF2). None of these proteins have been previously shown to impact SUMO pathways, although both BMRF1 and BVRF2 were shown to be SUMO-modified [32, 69]. Since global SUMOylation patterns can be caused by stress responses, it is possible that some of these proteins are eliciting a stress response [70]. Little is known about BVRF2 other than its conserved role as a scaffold protease [71]. BGLF2 is a viral tegument protein that has been found to induce p21 and interfere with G1/S cell cycle progression [28] and also to induce BZLF1 expression and the AP-1 signalling pathway through p38 and c-Jun N-terminal kinases activation [72, 73]. BMRF1 belongs to the family of DNA polymerase processivity factors that are conserved in all herpesviruses [74]. However, BMRF1 also has additional roles in transcriptional activation [75–77], cell cycle progression [28] and in inhibiting the DNA damage response to double stranded DNA breaks [34]. It will be interesting to determine how the multiple roles of BGLF2 and BMRF1 relate to their ability to upregulate SUMOylation.

One of the EBV proteins identified in our screens that globally upregulated SUMOylation was the SM (or EB2) protein that is conserved in other herpesviruses. SM and its homologues in HSV1 (UL54 or ICP27) and CMV (UL69) have conserved functions in RNA binding, splicing modulation and the export and translation of viral mRNA [45, 46, 48–51, 78]. In addition, several studies have identified roles for HSV1 UL54 in cell signalling and apoptosis [51, 79–81]. Our findings that SM, UL54 and UL69 induce SUMOylation suggests that the cellular effects of these proteins may be more extensive than is currently known. In addition, SUMOylation might play roles in the known functions of these proteins. While the role of SUMOylation in RNA splicing and mRNA transport has not been extensively studied, heterogeneous nuclear RNA binding proteins (hnRNPs), which have multiple roles in RNA splicing stabilization and export, are highly SUMOylated by both SUMO1 and SUMO2/3 [82–84]. In addition, the RanBP2/Nup358 component of the nuclear pore complex, which plays roles in mRNA export and translation, is a SUMO E3 ligase [36, 85, 86].

Our data suggest that SM, UL54 and UL69 are SUMO E3 ligases. These proteins not only upregulated SUMOylation in multiple cell systems, but bound directly to SUMO and Ubc9, as expected of SUMO E3 ligases. In addition, in a purified system using E.coli generated proteins, SM, UL54 and UL69 all induced SUMOylation of p53 in conjunction with Ubc9 and SAE. In cells, the three viral proteins varied in their abilities to induce SUMO1 vs SUMO2 modifications, with SM and UL69 preferentially inducing SUMO1 modifications and UL54 preferentially inducing SUMO2 modifications. This preference was also reflected in SUMO binding assays, where both immunoprecipitations from cells and in vitro SUMO binding assays showed that SM and UL69 preferentially bind SUMO1, while UL54 preferentially bind SUMO2. Preferences for SUMO1 or SUMO2/3 have been previously reported for some other SUMO binding proteins. For example, the KSHV K-bZIP and cellular ZNF451 SUMO E3 ligases have been shown to have specificity for SUMO2/3 over SUMO1, due to the presence of SIMs that preferentially bind SUMO2/3 over SUMO1 [13, 87, 88]. In contrast ORF61 of Varicella-Zoster virus (orthologue of the HSV1 ICP0 STUbL) preferentially binds SUMO1 [21]. SIMs can vary considerably in sequence, making them difficult to accurately predict by sequence analysis [89], and hence the SIMs in SM, UL54 and UL69 have yet to be determined.
SUMO E3 ligases are also difficult to predict since their sequence and structures vary considerably. The PIAS family of SUMO E3 ligases contain modified RING domains similar to RING-type ubiquitin ligases, however other SUMO E3 ligases, such as RANBP2 and K-bZIP, lack conserved catalytic domains [89, 90]. Zinc fingers have been found to be an important component of some E3 SUMO ligases, for example RANBP2 contains eight tandem zinc fingers and the ZNF451 family of SUMO E3 ligases contain 12 C2H2 zinc-finger domains [88, 91]. Interestingly, the structure of the C-terminal domain of ICP27 (UL54) revealed a novel CHCC-type zinc finger in which the zinc coordinating residues are conserved in UL54 homologues in other herpesviruses, including UL69 and SM [92, 93]. The conservation of this zinc-binding domain, and the presence of similar zinc binding domains in cellular SUMO E3 ligases, suggests that it might be an important component of the SUMO E3 ligase activity of SM, UL54 and UL69.

We have shown that p53 is one cellular protein that can be SUMOylated by SM, UL54 and UL69. p53 is known to be modified by either SUMO1 or SUMO2/3 at K386 [94]. The consequences of these modifications are a matter of debate, as there are reports that these modifications increase transcriptional activation by p53 and other reports that they decrease p53 activity [13, 94–97]. We showed that SM, UL54 and UL69 are all capable of inducing SUMO1 and SUMO2 modifications of p53 under in vitro conditions. In cells we also observed increased SUMOylation of p53 by these viral proteins, although SM and UL69 preferentially increased SUMO1 modification while UL54 increased SUMO2 modifications. This pattern parallels the global SUMOylation effects of these viral proteins. Whether or not p53 is an intended SUMOylation target of these viral proteins or whether other cellular proteins are preferential targets remains to be determined. Although SM, UL54 and UL69 globally upregulate SUMOylation under our assays conditions, we imagine that these proteins have preferred substrates during infection. Identifying these substrates will provide important insights into the functions and mechanisms of action of these proteins.

Our results build on the growing body of literature that manipulation of host SUMO pathways is important for lytic infection by herpesviruses. KSHV is known to express both a STUbL (Rta) and a SUMO2/3-specific SUMO E3 ligase (K-bZIP) in lytic infection, and SUMO2/3 modifications in general have been shown to suppress KSHV reactivation and expression of KSHV lytic genes [13, 15, 98, 99]. HSV1 is also known to encode a well-studied STUbL (ICP0)[16]. Our study provides the first identification of SUMO E3 ligases in HSV1, CMV and EBV, and also identifies EBV BRLF1 as a negative regulator of SUMOylation. To our knowledge, these are the first reports of EBV lytic proteins that globally affect SUMOylation. Previous studies on EBV and SUMOylation pathways have shown that LMP1 promotes latency by upregulating SUMOylation in EBV latent infection [30, 31], and that one of the EBV miRNAs expressed in lytic infection can promote SUMOylation by downregulating RNF4 [32]. In addition, several EBV proteins have been found to be SUMO modified, suggesting that their activities can be regulated by SUMOylation [32, 33, 39, 69]. It will be interesting to determine how the interplay between viral proteins that increase and decrease SUMOylation contribute to herpesvirus infections and why UL54 preferentially induces SUMO2 modifications while its homologues in EBV and CMV induce SUMO1 modifications.

Materials and methods

Plasmids

The EBV expression library was generated in pMZS3F for expression in mammalian cells, as previously described [28], such that proteins are expressed fused to a C-terminal calmodulin binding peptide and triple FLAG epitope. EBV SM in pcDNA3 (a generous gift from Sankar
Swaminathan) and EBV BRLF1 in pMZS3F were subcloned between the Sal I and Xba I sites in pCMV3FC, and HSV-1 UL54/ICP27 and CMV UL69 in pMZS3F were subcloned between the Xho I and Xba I sites in pCMV3FC, to generate proteins with C-terminal triple FLAG tags. Plasmids encoding EBV HA-tagged LMP1 (a gift from Nancy Raab-Traub) [100], HSV-1 ICP0 (pCI-110; a gift from Roger Everett) [101] and human His6-SUMO1 and His6-SUMO2 (in pcDNA3; gifts from Ronald T. Hay) [38, 102] for expression in mammalian cells have been previously described. For expression in E. coli, SM, UL54/ICP27 and UL69 coding sequences were excised from pCMV3FC using the restriction enzymes indicated above and were ligated into the corresponding sites of a modified pET15b with a multicloning site. To generate the modified pET15b, the Xba I site was mutated in pET15b then oligos (5'- CCA TGG GCA GCA GCC ATC ATC ATC ATC ATC ACA GCA GCG GCC TCG AGG CTA GCG TCG ACG GTA CCT CTA GAG ACG TAG CGG CCG CGG CGG ATC C -3') containing a multicloning sequence (Xho I, Nhe I, Sal I, KpnI, Xba I, Not I) were inserted between the Nco I and Bam HI sites of pET15b downstream of the hexahistidine tag. Oligos encoding a triple FLAG tag were then inserted between the Not I and Bam HI sites so that recombinant proteins contain N-terminal His6 and C-terminal 3FLAG tags. pGEX2T-SUMO1, pGEX2T-SUMO2 and pGEX2T-Ubc9 were kindly provided by Ronald T. Hay [103]. pcDNA4/TO plasmid expressing KSHV Rta (ORF50) with C-terminal Strep tag was a gift from Britt Glausinger and is described in Davis et al 2015 [104]. The plasmid expressing His-Myc-ubiquitin (pHis-Myc-Ub) was a gift from Filippo Giancotti [105]

Cell lines and transfections

HeLa cells (cervical carcinoma) containing integrated His6-SUMO1 or His6-SUMO2 (kindly provided by Ronald T. Hay; [106]) and 293T cells (embryonic kidney; ATCC) were cultured in DMEM with 10% FBS. CNE2Z cells (EBV-negative nasopharyngeal carcinoma [107]; a gift from Fei-Fei Liu) were cultured in α-MEM with 10% FBS. AGS-EBV cells (EBV- positive gastric carcinoma [108]; a gift from Lindsay Hutt-Fletcher) were grown in RPMI with 10% FBS. All cells were plated 24 hrs before transfection and transfected at a confluency of 70–80% using PolyJet (FroggaBio) or Lipofectamine 2000 (Life Technologies) or linear polyethyleneimine (PEI; Polyscience Inc. catalogue number 23966), as suggested by the manufacturer.

Western blotting and antibodies

Protein fractions were separated by SDS-PAGE (8% to 15% depending on the experiment) and transferred onto nitrocellulose. Membranes were blocked with 1% BSA in PBS-Tween 0.1% (PBS-T) for 1 h, followed by incubation with primary antibodies in blocking buffer overnight at 4°C. Membranes were washed three times with PBS-T for 10 min and then incubated with secondary antibodies conjugated to horseradish peroxidase in blocking buffer for 1 h. Membranes were washed four times with PBS-T for 15 min, and signals were detected by enhanced chemiluminescence (Santa Cruz sc-2048 or Biorad Clarity 1705061). Antibodies to SUMO1 (FL-101, 1:1000 dilution), SUMO2 (FL-103, 1:2000 dilution), Ubc9 (H-81, 1:500 dilution), His (H-15, 1:500 dilution), p53 (DO-1, 1:5000 dilution), myc (sc-40; 1:2000 dilution) and actin (C-11, 1:2000 dilution) were from Santa Cruz. Antibodies to PML (A301-167A, 1:2000 dilution), GST (A190-122A; 1:10,000) and FLAG (A90-102, 1:10000 dilution) were from Bethyl. Anti-FLAG (F1804, 1:10000 dilution) was from SIGMA and anti-ICP0 (H1A027, 1:5000 dilution) was from Virusys. RNF4 antibody (a kind gift from Ronald T. Hay; [109]) and was used at 1:5000 dilution.
Global SUMOylation screen

293T and CNE2Z cells in 6 well dishes were co-transfected with plasmids (0.5 μg each) expressing His6-SUMO1 or His6-SUMO2 and FLAG-tagged viral proteins (in pMIZS3F or pCMV3FC) or LMP1 (positive control for SUMO upregulation) or ICP0 (positive control for SUMO downregulation) or empty plasmid negative control. HeLa cells containing integrated His6-SUMO1 or His6-SUMO2 were similarly transfected with 0.5 μg of plasmids expressing FLAG-tagged viral proteins, ICP0 or LMP1 or empty plasmid control. His6-tagged SUMO conjugates were purified under denaturing conditions essentially as previously described [106]. Briefly, approximately 2 x 10^6 cells were harvested 36 hrs post transfection. 10% of the cells were lysed in 2X SDS loading buffer (60 mM Tris.HCl pH 6.8, 1% SDS, 100 mM DTT, 5% glycerol) to provide the input sample. 90% of the cells were resuspended in 0.5 ml lysis buffer G (6 M guanidine hydrochloride, 10 mM Tris, 100 mM sodium phosphate, pH 8.0) and incubated on ice 20 min. Lysates were passed through a 30G needle five times. Then, lysates were added 50 μl of TALON Metal Affinity Resin (Clontech) previously equilibrated with lysis buffer, and incubated 3 hrs at room temperature with end-over-end rotation. The resin was washed four times with 1 ml of wash buffer U (8 M urea, 10 mM Tris, 100 mM sodium phosphate, pH 8.0) and proteins were eluted in 2X SDS loading buffer. Inputs and purified fractions were analyzed by Western blotting with SUMO1, SUMO2, FLAG and actin antibodies.

RNF4 silencing

For SUMOylation experiments involving RNF4 silencing, CNE2Z were plated in a 6-well dish at 10% confluency and transfected with either 40 pmoles of Stealth siRNF4 (Invitrogen) or Qiagen Allstars control siRNA with Lipofectamine 2000 (ThermoFisher Scientific) according to the manufacturer’s instructions. The transfection was repeated after 24 hours. 9 hours later the cells were transfected (using PEI) with 1 μg of pCMV3FC, pCI-110 (expressing ICP0) or pCMV3FC-BRLF1 and 1 μg of plasmids expressing His6-SUMO1 or His6-SUMO2. Cells were harvested 39 hours later and lysed in 150 μl of 8 M urea buffer (8 M urea, 20 mM Tris pH 8, 100 mM NaCl, protease inhibitor cocktail (P8849; Sigma)). Lysates were sonicated and clarified by centrifugation. 360 μg of clarified lysate was incubated with 50 μl equilibrated TALON resin for 2 hours at RT with mixing, followed by washing and elution as above. Elutions were analysed by 8% SDS-PAGE and Western blotting for SUMO1, SUMO2, FLAG (BRLF1) and actin (Thermofisher).

Effect of MG132 on endogenous SUMOylation by BRLF1

293T cells in 6 well dishes were transfected with 2 μg plasmid expressing ICP0 or FLAG-tagged BRLF1 using PEI according to the manufacturer’s protocol. For one set of samples, MG132 (Sigma) was added to 10 μM 24 hours post-transfection and 10 hours prior to harvesting. All samples were harvested 34 hours post-transfection and lysed in 9 M urea, 10 mM Tris pH 6.8 with sonication. 40 μg of clarified lysates were analysed on 8% SDS-PAGs followed by Western blotting with antibodies against SUMO1, SUMO2, FLAG, ICP0 and actin.

Ubiquitylation assay

CNE2Z or 293T in 6 well dishes were transfected with PEI with 1 μg pCMV-3FC, pCI-110 (expressing ICP0), pcDNA4/TO expressing Strep-tagged KSHV Rta or pCMV3FC-BRLF1 and 1 μg of plasmid expressing His-Myc-ubiquitin [105]. 24 hours later, MG132 (Cell Signalling, 2194S) was added to 10 μM for 10 hours. Cells were harvested and lysed in 150 μl (CNE2Z) or
300 μl (293T) 8M urea buffer (8M urea, 20 mM Tris pH 8, 100 mM NaCl, protease inhibitor cocktail (Sigma P8849)). Lysates were sonicated and centrifuged to clarify. 50 μg (CNE2Z) or 160 μg (293T) of lysate was added to 50 μl TALON resin (prewashed with 8M urea buffer), followed by incubation, washing and elution as described above for SUMOylation screen. 30 μl of elutions and 30 μg of clarified lysates were analysed by Western blotting using anti-myc antibody. Input lysate were also probed with antibodies against FLAG (BRLF1), ICP0 and Strep (KSHV Rta).

**PML nuclear bodies (NB) and protein analyses**

Immunofluorescence microscopy analysis was performed as described previously [45]. Briefly, CNE2Z cells on cover slips were transfected with plasmids expressing ICP0 (pCI-110) or FLAG-tagged BRLF1 (in pCMV3FC), fixed 24 hrs post transfection and stained with antibodies against PML and ICP0 or FLAG. PML NBs were counted in 50 cells for each sample in two independent experiments. For PML Western blots, cells were transfected as described above and, 48 hrs post transfection, cells were lysed in 9M urea buffer (9M urea, 10 mM Tris pH 6.8). 40 μg of clarified lysates were loaded onto 10% SDS-PAGE, transferred onto nitrocellulose and analyzed by Western blotting with PML, ICP0 and FLAG antibodies.

**Analysis of endogenous SUMOylation**

293T cells in 12 well plates were transfected with 0.5 μg plasmid expressing LMP1, ICP0 or the indicated FLAG-tagged EBV protein. 36 hrs later, 1 x 10^6 293T cells were lysed in passive lysis buffer (Promega E194A). 50 μg of clarified lysates were loaded onto 8% SDS-PAGE, transferred to nitrocellulose and analyzed by Western blotting with SUMO1, SUMO2, FLAG and actin antibodies.

**SUMO1, SUMO2 and Ubc9 interactions in human cells**

To evaluate the interaction of SM, UL54, and UL69 with SUMO proteins, HeLa cells containing integrated His6-SUMO1 or His6-SUMO2 in 6 cm dishes were transfected with 2.5 μg of pCMV3FC plasmids expressing FLAG-tagged SM, UL54 or UL69 or with pCMV3FC alone. 36 hrs later, cells were harvested and lysed in RIPA buffer without EDTA [50 mM Tris pH 8.0, 200 mM NaCl, 1.0% (v/v) NP-40, 0.5% (w/v) sodium deoxycholate, protease inhibitor cocktail SIGMA P8340]. Lysates (1 mg) were subjected to His-pull down using 100 μl of Ni-NTA agarose (Qiagen) for 2 hrs at 4°C with mixing, and beads were then washed four times with 1 ml of RIPA buffer. Proteins were eluted in 2X SDS loading buffer and analyzed by Western blotting with antibodies against FLAG and His. To evaluate the interaction of SM, UL54, and UL69 with Ubc9, 293T cells were transfected as described above, and 36 hrs post-transfection cells were lysed in RIPA buffer. 2 mg of lysate was incubated overnight at 4°C with 25 μg of agarose-conjugated Ubc9 antibody (C-12; Santa Cruz), with mixing, then beads were washed four times with 1 ml of RIPA buffer. Proteins were eluted in 2X SDS loading buffer and analyzed by Western blotting with FLAG and Ubc9 antibodies.

**Protein purification from E.coli for in vitro assays**

Recombinant His6-SM-3FLAG, His6-UL54-3FLAG and His6-UL69-3FLAG proteins were generated in E. coli for in vitro assays. BL21-pLysS E. coli containing pET15b-SM-3FLAG, pET15b-UL54-3FLAG or pET15b-UL69-3FLAG were grown in Luria broth (LB) to OD SO 0.6 then protein expression was induced with 1 mM IPTG overnight at 18°C. Bacteria from 1 L of culture were resuspended in 20 ml of binding buffer (50 mM sodium phosphate, 300 mM
NaCl, 5 mM imidazole, protease inhibitor cocktail, pH 7.8) and lysed with 3 rounds of sonication for 20 sec each. Lysates were clarified by centrifugation at 10000 x g for 20 min at 4˚C and then incubated with 400 μl of Ni-NTA agarose (Qiagen) for 1 h at 4˚C with mixing. Agarose was washed 4 times with 2 ml washing buffer (50 mM sodium phosphate, 300 mM NaCl, 20 mM imidazole, protease inhibitor cocktail, pH7.6), then transferred into a gravity-flow column and washed once more with 2 ml washing buffer. Proteins were eluted with 1 ml of elution buffer (50 mM sodium phosphate, 300 mM NaCl, 200 mM imidazole, protease inhibitor cocktail, pH7.4) and collected in 200 μl fractions. Hexahistidine-tagged full length p53 with L344P point mutation (rendering it monomeric) was expressed and purified from E.coli as described previously [52].

GST, GST-SUMO1, GST-SUMO2 and GST-Ubc9 were generated by standard methods. Briefly, DH5α E. coli containing pGEX-2T expression plasmids were grown in LB to OD₅₈₀ 0.6, then protein expression was induced with 1 mM IPTG for 2 hrs at 37˚C. Bacteria from 1 L of culture were resuspended in 20 ml of PBS supplemented with 1% Triton X-100 and 1 mM PMSF, and lysed with 3 rounds of sonication for 20 sec each. Lysates were clarified by centrifugation at 10000 x g for 20 min at 4˚C and then incubated with 500 μl of Glutathione Sepharose 4B (GE life sciences) for 2 hrs at 4˚C with mixing. Resin was washed 4 times with 2 ml PBS-TritonX100-PMSF, then resuspended in 0.5 ml PBS with 1 mM PMSF and stored at -80˚C.

In vitro binding assays with SM, UL54, UL69

GST-pull down assays were performed to evaluate the interaction of purified, recombinant SM, UL54 and UL69 with GST-tagged SUMO1, SUMO2 and Ubc9. To this end, GST-tagged proteins (or GST alone) bound to glutathione resin (described above) were blocked with 2% BSA in PBS for 2 hrs at 4˚C then levels of the GST proteins were evaluated by SDS-PAGE and Coomassie blue staining. Equal amounts of GST-SUMO1, GST-SUMO2, GST-Ubc9 or GST control bound to resin (corresponding to ~2 μg of full length protein) were combined with equal amounts (~1 μg as estimated from Coomassie stained SDS-PAGs) of full-length recombinant His6-SM-3FLAG, His6-UL54-3FLAG or His6-UL69-3FLAG (partially purified from E. coli as described above) in 150 μl binding buffer (20 mM Tris pH 8.0, 200 mM NaCl, 0.2 mM EDTA, 10% glycerol, 0.1% Triton X-100, protease inhibitor cocktail) for 3 hrs at 4˚C with mixing. The resin was then washed with 1 ml of binding buffer four times and proteins eluted in 2X SDS loading buffer. 10% of the elution was loaded onto 15% SDS-PAGE and subjected to Coomassie staining. 90% of the elution was analyzed by western blotting with anti-FLAG antibody.

In vitro SUMO binding assay with BRLF1

10 cm dishes of 293T were transfected with 8 μg each pCMV3FC or pCMV3FC-BRLF1 using 24 μl of PEI according to the manufacturer’s protocol. Cells were harvested 48 hours later and lysed in 50 mM Tris pH 8.0, 1 M NaCl, 0.1% sodium deoxycholate, 0.5% NP40, 2 mM EDTA, protease inhibitor cocktail (P8340; Sigma). Cells were lysed by sonication and lysates clarified by centrifugation. Protein concentrations were adjusted to 6.5 mg/ml and 600 μl of lysate was incubated with 5 μl equilibrated anti-FLAG M2 resin (Sigma A2220) for 2 hours. The resin was washed twice with 1 ml lysis buffer, twice with 1 ml BC100 (20mM Tris pH7.9, 100mM NaCl, 10% glycerol, 0.2mM EDTA, 0.2% TritonX100, protease inhibitor cocktail (Sigma P8849)) then blocked by 2 hr incubation in 1 ml BC100 containing 2% BSA. Bacterial lysates containing equivalent amounts of GST, GST-SUMO1 or GST-SUMO2 (generated as above except using BC100 lysis buffer) diluted to 100 μl in BC100/2%BSA were then added to the FLAG resin. The resin was washed five times with 1 ml BC100 containing 1% TritonX-100.
and eluted in 2X SDS loading buffer. 20% of the elutions and 20% of the equivalent GST inputs were run analysed by SDS-PAGE and Coomassie staining to compare levels of input proteins. The remaining elutions (and 1% of the GST inputs) were analysed by Western blotting using anti-GST antibody and goat-anti rabbit secondary antibody (SAB3700878; 1:5000).

**In vitro SUMOylation of p53**

Assays for *in vitro* SUMOylation of p53 were performed using the SUMOylation Assay Kit from Abcam (ab139470), as suggested by the manufacturer. 10 μl reactions included 50 ng of recombinant p53 as substrate (purified from *E.coli* as indicated above) and varying amounts (~100, 200 and 400 ng) of recombinant His6-SM-3FLAG, His6-UL54-3FLAG or His6-UL69-3FLAG (partially purified from *E.coli* as described above). Reactions with no viral proteins or with viral proteins but no SAE were included as negative controls. Reactions were incubated 1.5 hrs at 37˚C and stopped by the addition of 2X SDS loading buffer. The presence of viral proteins and the SUMOylation of p53 were evaluated by Western blotting with FLAG, p53, SUMO1 and SUMO2 antibodies.

**SUMOylation of p53 in human cells**

293T cells were co-transfected with plasmids expressing His6-SUMO1 or His6-SUMO2 and pCMV3FC expressing FLAG-tagged SM, UL54 or UL69 or empty pCMV3FC or positive control LMP1 and ICP0 plasmids as describe above for the SUMO screen. 36 hrs post transfection, 10% of the cells were lysed in 2X SDS loading buffer (input fraction) and 90% of the cells were lysed in lysis buffer G followed by purification of His-tagged SUMO conjugates on metal chelating resin as described above. Inputs and purified fractions were analyzed by western blotting with p53 and FLAG antibodies.

**SM expression and silencing in AGS-EBV cells**

AGS-EBV cells in 6-well dishes were transfected with 100 pmoles of SM-specific siRNA (5’-GCUGCACCAGUAAGUATT-3’) or AllStars negative-control siRNA (Qiagen) using 2 μl of Lipofectamine 2000 (Thermo Fisher Scientific). Two additional rounds of silencing were performed after 24 and 48 hours. Twenty-four hours later, cells were treated with 3 mM sodium butyrate (NaB) and 20 ng/ml 12-O-tetradecanoylphorbol-13-acetate (TPA) to induce the lytic cycle and harvested at 0, 8, 16, 24 and 48 hours post-treatment for reverse-transcriptase quantitative PCR (qRT-PCR) of SM transcripts and Western blot analysis. For qRT-PCR, total RNA was extracted using TRIzol (Invitrogen) according to the manufacturer’s instructions. One microgram of total RNA was treated with 0.5 units of DNase I (New England BioLabs) for 15 min and reverse transcribed in a 20 μl reaction mixture using the SuperScript IV reverse transcriptase (Invitrogen) with random hexamer primers according to the manufacturer’s instructions. qRT-PCR was performed with 1 μl of 1:10 dilution of the cDNA using Luna Universal qPCR Master Mix (New England BioLabs) with a total reaction volume of 10 μl in a Bio-Rad CFX384 Real-Time System (Bio-Rad). Primers used were: SM forward 5’-CCTGCGTCAATCCAGAGC-3’, SM reverse 5’-CTGCGTCAATCCAGAGC-3’, β-actin forward 5’-GGACATTGGGTTTTGAGATGG-3’ and β-actin reverse 5’-AGCAGTTGTTGGC GTACAG-3’. The relative mRNA expression level was derived from 2-ΔΔCT by use of the comparative threshold cycle (CT) method. The amount of mRNA in each sample was normalized to the amount of actin mRNA. For Western blot analyses, Cells were lysed in 9 M urea-10 mM Tris (pH 6.8) followed by sonication and clarification by centrifugation. Twenty micrograms of clarified lysates were analysed by 8% SDS-PAGE and Western blotting using antibodies against SUMO1 (rabbit, 1:1000 dilution, sc-9060, Santa Cruz) or β-actin (mouse, 1:10,000 dilution).
dilution, sc-47778, Santa Cruz) and secondary antibodies goat-anti-rabbit (1:5000 dilution, SAB3700878-1, Sigma) or goat anti-mouse (1:5000 dilution, sc-2005, Santa Cruz).

Supporting information
S1 Fig. Screens of EBV proteins for global effects on cellular SUMO1 and SUMO2 modifications. Western blots from Fig 1A and 1B but including blots for LMP1 (HA antibody; Cell Signalling #3724) and ICP0.

S2 Fig. SM and BMRF1 are SUMO2-modified. 293T cells in 6 well dishes were co-transfected with plasmids (0.5 μg each) expressing FLAG-tagged SM or BMRF1 and His6-SUMO1, His6--SUMO2 or empty vector. Cells were harvested 36 hrs post transfection. 10% of the cells were lysed in 2X SDS loading buffer (60 mM Tris.HCl pH 6.8, 1% SDS, 100 mM DTT, 5% glycerol) to provide the input sample. 90% of the cells were resuspended in 0.5 ml lysis buffer G (6 M guanidine hydrochloride, 10 mM Tris, 100 mM sodium phosphate, pH 8.0) and subjected to purification of His-tagged SUMO conjugates as described in Materials and Methods. Inputs and purified fractions were analyzed by Western blotting with FLAG antibody. Arrowheads indicate non-modified SM or BMRF2. Stars indicate SUMO conjugated SM or BMRF1.

S3 Fig. SM, UL54, UL69 and BRLF1 do not affect SUMO transcripts. 293T cells in 6 cm dishes were transfected with 2.5 μg of pCMV expressing SM, UL54, UL69, BRLF1 or empty pCMV (EV). 36 hrs later, total RNA was isolated from cells using the Trizol regent (Life Technologies). 1 μg of total RNA was reverse transcribed in a 25 μl reaction using SuperScript IV reverse transcriptase (Life Technologies) and random hexamer primers as suggested by the manufacturer. Quantitative real time PCR was performed according to the manufacturer’s recommendation using 1 μl of a 1:10 dilution the cDNA and Luna Universal qPCR mix (New England Biolabs) with a total reaction volume of 10 μl in a Bio-Rad CFX384 Real-Time System (Bio-Rad). Primers used to quantify mRNA levels were: SUMO1 forward 5’- GGGAAGGGAG AAGATTTGTAA-3’, SUMO1 reverse 5’- GTCCCTAGTTGAAGTTTTGC-3’, SUMO2 forward 5’-GCAGACGGGAGGTGTCT ACT-3’, SUMO2 reverse 5’-AGTCAGGATGTGGTG TGAACC-3’, Ubc9 forward 5’-ATTATCCATCTTCGCCACCA-3’, Ubc9 reverse 5’-TCTT GCCAACACAATCTCCT-3’, β-actin forward 5’-GGACTTGCAGCAAGGAGATGG-3’ and β-actin reverse 5’-AGCAGTGTGTTGGCGTACAG-3’. The relative mRNA expression level was derived from 2–ΔΔCT by use of the comparative threshold cycle (CT) method. The amount of mRNA in each sample was normalized to the amount of actin mRNA. The average values (with standard deviation) from two independent experiments are shown for SUMO1 (A), SUMO2 (B) and Ubc9 (C). A positive control for induction of these transcripts is also shown, generated by treatment of cells with the empty plasmid (EV) with sodium butyrate and TPA (Bu/TPA).

Acknowledgments
We are grateful to Dr. Ron Hay for providing His6-SUMO HeLa cells, RNF4 antibody, E.coli expression plasmids for GST-SUMO1, GST-SUMO2 and GST-Ubc9 and mammalian expression plasmids for His6-SUMO1 and His6-SUMO2. We also thank Shili Duan and Dr. Cheryl Arrowsmith for providing purified p53, Britt Glausinger for KSHV Rta expression plasmid and Alvin Yang for technical assistance.
Author Contributions

Conceptualization: Carlos F. De La Cruz-Herrera.
Formal analysis: Carlos F. De La Cruz-Herrera, Kathy Shire.
Funding acquisition: Lori Frappier.
Investigation: Carlos F. De La Cruz-Herrera, Kathy Shire, Umama Z. Siddiqi.
Methodology: Carlos F. De La Cruz-Herrera, Kathy Shire, Umama Z. Siddiqi.
Supervision: Lori Frappier.
Writing – original draft: Carlos F. De La Cruz-Herrera, Umama Z. Siddiqi, Lori Frappier.
Writing – review & editing: Carlos F. De La Cruz-Herrera, Kathy Shire, Lori Frappier.

References

1. Eifler K, Vertegaal AC. SUMOylation-Mediated Regulation of Cell Cycle Progression and Cancer. Trends Biochem Sci. 2015 Dec; 40(12):779–93. https://doi.org/10.1016/j.tibs.2015.09.006 PMID: 26601932

2. Flothey A, Melchior F. Sumoylation: a regulatory protein modification in health and disease. Annu Rev Biochem. 2013; 82:357–85. https://doi.org/10.1146/annurev-biochem-061909-093311 PMID: 23746258

3. Rabellino A, Andreani C, Scaglioni PP. The Role of PIAS SUMO E3-Ligases in Cancer. Cancer Res. 2017 Apr 01; 77(7):1542–7. https://doi.org/10.1158/0008-5472.CAN-16-2958 PMID: 28330929

4. Seeler JS, Dejean A. SUMO and the robustness of cancer. Nat Rev Cancer. 2017 Mar; 17(3):184–97. https://doi.org/10.1038/nrc.2016.143 PMID: 28134258

5. Bellail AC, Olson JJ, Hao C. SUMO1 modification stabilizes CDK6 protein and drives the cell cycle and glioblastoma progression. Nat Commun. 2014 Jun 23; 5:4234. https://doi.org/10.1038/ncomms5234 PMID: 24953629

6. Yang W, Wang L, Roehn G, Pearlstein RD, Ali-Osman F, Pan H, et al. Small ubiquitin-like modifier 1–3 conjugation [corrected] is activated in human astrocytic brain tumors and is required for glioblastoma cell survival. Cancer Sci. 2013 Jan; 104(1):70–7. https://doi.org/10.1111/cas.12047 PMID: 23078246

7. Hoellein A, Fallahi M, Schoeffmann S, Steidle S, Schaub FX, Rudelius M, et al. Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma. Blood. 2014 Sep 25; 124(13):2081–90. https://doi.org/10.1182/blood-2014-05-584524 PMID: 25143484

8. Varadaraj A, Mattoscio D, Chiocca S. SUMO Ubc9 enzyme as a viral target. IUBMB Life. 2014 Jan; 66 (1):27–33. https://doi.org/10.1002/iub.1240 PMID: 24395713

9. Heaton PR, Deyriex AF, Bian XL, Wilson VG. HPV E6 proteins target Ubc9, the SUMO conjugating enzyme. Virus Res. 2011 Jun; 158(1–2):199–208. https://doi.org/10.1016/j.virusres.2011.04.001 PMID: 21510985

10. Pennella MA, Liu Y, Woo JL, Kim CA, Berk AJ. Adenovirus E1B 55-kilodalton protein is a p53-SUMO1 E3 ligase that represses p53 and stimulates its nuclear export through interactions with promyelocytic leukemia nuclear bodies. J Virol. 2010 Dec; 84(23):12210–25. https://doi.org/10.1128/JVI.01442-10 PMID: 20861261

11. Muller S, Dobner T. The adenovirus E1B-55K oncoprotein induces SUMO modification of p53. Cell Cycle. 2008 Mar 15; 7(6):754–8. https://doi.org/10.4161/cc.7.6.459 PMID: 18461721

12. Sohn SY, Hearing P. The adenovirus E4-ORF3 protein functions as a SUMO E3 ligase for TIF-1gamma sumoylation and poly-SUMO chain elongation. Proc Natl Acad Sci U S A. 2016 Jun 14; 113 (24):7225–30. https://doi.org/10.1073/pnas.1603872113 PMID: 27247397

13. Chang PC, Izumiya Y, Wu CY, Fitzgerald LD, Campbell M, Ellison TJ, et al. Kaposi’s sarcoma-associated herpesvirus (KSHV) encodes a SUMO E3 ligase that is SIM-dependent and SUMO-2/3-specific. J Biol Chem. 2010 Feb 18; 285(6):5266–73. https://doi.org/10.1074/jbc.M108.088088 PMID: 20034935

14. Wimmer P, Schreiner S. Viral Mimicry to Usurp Ubiquitin and SUMO Host Pathways. Viruses. 2015 Sep; 7(9):4854–72. https://doi.org/10.3390/v7092849 PMID: 26343706

15. Izumiya Y, Kobayashi K, Kim KY, Pochampalli M, Izumiya C, Shevchenko B, et al. Kaposi’s sarcoma-associated herpesvirus K-Rta exhibits SUMO-targeting ubiquitin ligase (STUbL) like activity and is
Bentz GL, Shackelford J, Pagano JS. Epstein-Barr virus latent membrane protein 1 regulates the function of interferon regulatory factor 7 by inducing its sumoylation. J Virol. 2012 Nov; 86(22):12251–61. PMID: 23990779

Boutell C, Everett RD. Regulation of alphaherpesvirus infections by the ICP0 family of proteins. J Gen Virol. 2013 Mar; 94(Pt 3):465–81. https://doi.org/10.1099/vir.0.048900-0 PMID: 23239572

Sriramachandran AM, Dohmen RJ. SUMO-targeted ubiquitin ligases. Biochim Biophys Acta. 2014 Jan; 1843(1):75–85. https://doi.org/10.1016/j.bbamer.2013.08.022 PMID: 24018209

Dong X, He Z, Durakoglugil D, Arneson L, Shen Y, Feng P. Murine gammaherpesvirus 68 evades host cytokine production via replication transactivator-induced RelA degradation. J Virol. 2012 Feb; 86(4):1930–41. https://doi.org/10.1128/JVI.016127-11 PMID: 22130545

Boutell C, Cuchet-Lourenco D, Vanni E, Orr A, Glass M, McFarlane S, et al. A viral ubiquitin ligase has substrate preferential SUMO targeted ubiquitin ligase activity that counteracts intrinsic antiviral defence. PLoS Pathog. 2011 Sep; 7(9):e1002245. https://doi.org/10.1371/journal.ppat.1002245 PMID: 21949651

Pichler A, Gast A, Seeler JS, Dejean A, Melchior F. The nucleoporin RanBP2 has SUMO1 E3 ligase activity. Cell. 2002 Jan 11; 108(1):109–20. PMID: 11792325
37. Wong KA, Kim R, Christofk H, Gao J, Lawson G, Wu H. Protein inhibitor of activated STAT Y (PIASy) and a splice variant lacking exon 6 enhance sumoylation but are not essential for embryogenesis and adult life. Mol Cell Biol. 2004 Jun; 24(12):5577–86. https://doi.org/10.1128/MCB.24.12.5577-5586.2004 PMID: 15169916

38. Vertegaal AC, Andersen JS, Ogg SC, Hay RT, Mann M, Lamond AI. Distinct and overlapping sets of SUMO-1 and SUMO-2 target proteins revealed by quantitative proteomics. Mol Cell Proteomics. 2006 Dec; 5(12):2298–310. https://doi.org/10.1074/mcp.M600212-MCP200 PMID: 17000644

39. Yang YC, Yoshikai Y, Hsu SW, Saitoh H, Chang LK. Role of RNF4 in the ubiquitination of Rta of Epstein-Barr virus. J Biol Chem. 2013 May 3; 288(18):12866–79. https://doi.org/10.1074/jbc.M112.413393 PMID: 23504328

40. Yu Y, Wang SE, Hayward GS. The KSHV immediate-early transcription factor RTA encodes ubiquitin E3 ligase activity that targets IRF7 for proteosome-mediated degradation. Immunity. 2005 Jan; 21(1):59–70. https://doi.org/10.1016/j.immuni.2004.11.011 PMID: 15664159

41. Lanfranca MP, Mostafa HH, Davido DJ. HSV-1 ICP0: An E3 Ubiquitin Ligase That Counteracts Host Intrinsic and Innate Immunity. Cells. 2014; 3(2):438–54. https://doi.org/10.3390/cells3020438 PMID: 24852129

42. Geoffroy MC, Chelbi-Alix MK. Role of promyelocytic leukemia protein in host antiviral defense. J Interferon Cytokine Res. 2011 Jan; 31(1):145–58. https://doi.org/10.1089/jir.2010.0111 PMID: 21198351

43. Everett RD. DNA viruses and viral proteins that interact with PML nuclear bodies. Oncogene. 2001 Oct 29; 20(49):7266–73. https://doi.org/10.1038/sj.onc.1204759 PMID: 11704855

44. Cuchet-Lorenco D, Vanni E, Glass M, Orr A, Everett RD. Herpes simplex virus 1 ubiquitin ligase ICP0 interacts with PML isoform I and induces its SUMO-independent degradation. J Virol. 2012 Oct; 86(20):11209–22. https://doi.org/10.1128/JVI.01145-12 PMID: 22875967

45. Han Z, Marendy E, Wang YD, Yuan J, Sample JT, Swaminathan S. Multiple roles of Epstein-Barr virus SM protein in lytic replication. J Virol. 2007 Apr; 81(8):4058–69. https://doi.org/10.1128/JVI.02665-06 PMID: 17287267

46. Verma D, Bais S, Gaillard M, Swaminathan S. Epstein-Barr Virus SM protein utilizes cellular splicing factor SRp20 to mediate alternative splicing. J Virol. 2010 Nov; 84(22):11781–9. https://doi.org/10.1128/JVI.01359-10 PMID: 20810723

47. Nicewonger J, Suck G, Bloch D, Swaminathan S. Epstein-Barr virus (EBV) SM protein induces and recruits cellular Sp110b to stabilize mRNAs and enhance EBV lytic gene expression. J Virol. 2004 Sep; 78(17):9412–22. https://doi.org/10.1128/JVI.78.17.9412-9422.2004 PMID: 15308735

48. Verma D, Swaminathan S. Epstein-Barr virus SM protein functions as an alternative splicing factor. J Virol. 2008 Jul; 82(14):7180–8. https://doi.org/10.1128/JVI.00344-08 PMID: 18463151

49. Hiriart E, Farjot G, Gruffat H, Nguyen MV, Sergeant A, Manet E. A novel nuclear export signal and a REF interaction domain both promote mRNA export by the Epstein-Barr virus EB2 protein. J Biol Chem. 2003 Jan 03; 278(1):335–42. https://doi.org/10.1074/jbc.M208652000 PMID: 12403791

50. Toth Z, Stammingter T. The human cytomegalovirus regulatory protein UL69 and its effect on mRNA export. Front Biosci. 2008 Jan 01; 13:2939–49. PMID: 17981767

51. Sandri-Goldin RM. The many roles of the highly interactive HSV protein ICP27, a key regulator of infection. Future Microbiol. 2011 Nov; 6(11):1261–77. https://doi.org/10.2217/fmb.11.119 PMID: 22082288

52. Davison TS, Yin P, Nie E, Kay C, Arrowsmith CH. Characterization of the oligomerization defects of two p53 mutants found in families with Li-Fraumeni and Li-Fraumeni-like syndrome. Oncogene. 1998 Aug 6; 17(5):651–6. https://doi.org/10.1038/sj.onc.1202062 PMID: 9704931

53. Wu SY, Chiang CM. p53 sumoylation: mechanistic insights from reconstitution studies. Epigenetics. 2009 Oct 1; 4(7):445–51. PMID: 19838051

54. Sewatano J, Ling PD. Murine gammaherpesvirus 68 ORF75c contains ubiquitin E3 ligase activity and requires PML SUMOylation but not other known cellular PML regulators, CK2 and E6AP, to mediate PML degradation. Virology. 2013 Jun 5; 440(2):140–9. https://doi.org/10.1016/j.virol.2013.02.014 PMID: 23541081

55. Ahn JH, Hayward GS. The major immediate-early proteins IE1 and IE2 of human cytomegalovirus colocalize with and disrupt PML-associated nuclear bodies at very early times in infected permissive cells. J Virol. 1997 Jun; 71(6):4599–613. PMID: 9151854

56. Lee HR, Kim DJ, Lee JM, Choi CY, Ahn BY, Hayward GS, et al. Ability of the human cytomegalovirus IE1 protein to modulate sumoylation of PML correlates with its functional activities in transcriptional regulation and infectivity in cultured fibroblast cells. J Virol. 2004 Jun; 78(12):6527–42. https://doi.org/10.1128/JVI.78.12.6527-6542.2004 PMID: 15163746
57. Adamson AL, Kenney S. Epstein-Barr virus immediate-early protein BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia bodies. J Virol. 2001 Mar; 75(5):2388–99. https://doi.org/10.1128/JVI.75.5.2388-2399.2001 PMID: 11160742

58. Ehmann GL, McLean TI, Bachenheimer SL. Herpes simplex virus type 1 infection imposes a G(1)/S block in asynchronously growing cells and prevents G(1) entry in quiescent cells. Virology. 2000 Feb 15; 267(2):335–49. https://doi.org/10.1006/viro.1999.0147 PMID: 10662629

59. Dittmer D, Mocarski ES. Human cytomegalovirus infection inhibits G1/S transition. J Virol. 1997 Feb; 71(2):1629–34. PMID: 8995690

60. Lu M, Shenk T. Human cytomegalovirus infection inhibits G1/S transition at multiple points, including the transition from G1 to S. J Virol. 1996 Dec; 70(12):8850–7. PMID: 8995690

61. Rodriguez A, Jung EJ, Flemington EK. Cell cycle analysis of Epstein-Barr virus-infected cells following treatment with lytic cycle-inducing agents. J Virol. 2001 May; 75(10):4482–9. https://doi.org/10.1128/JVI.75.10.4482-4489.2001 PMID: 11312318

62. Smith S, Weller SK. HSV-I and the cellular DNA damage response. Future Virol. 2015 Apr; 10(4):383–97. https://doi.org/10.2217/fvl.15.18 PMID: 26213561

63. Lilley CE, Chaurushiya MS, Boutell C, Everett RD, Weitzman MD. The intrinsic antiviral defense to incoming HSV-1 genomes includes specific DNA repair proteins and is counteracted by the viral protein ICP0. PLoS Pathog. 2011 Jun; 7(6):e1002084. https://doi.org/10.1371/journal.ppat.1002084 PMID: 21689222

64. Xiaofei E, Kowalik TF. The DNA damage response induced by infection with human cytomegalovirus and other viruses. Viruses. 2014 May 23; 6(5):2155–85. https://doi.org/10.3390/v6052155 PMID: 24859341

65. Ho TH, Sitz J, Shen Q, Leblanc-Lacroix A, Campos EI, Borozan I, et al. A Screen for Epstein-Barr Virus Proteins that Inhibit the DNA Damage Response Reveals a Novel Histone Binding Protein. J Virol. 2018 May 9.

66. Liu Y, Bridges R, Wortham A, Kulesz-Martin M. NF-kappaB repression by PIAS3 mediated RelA SUMOylation. PLoS ONE. 2012; 7(5):e37636. https://doi.org/10.1371/journal.pone.0037636 PMID: 22649547

67. Chang LK, Lee YH, Cheng TS, Hong YR, Lu PJ, Wang JJ, et al. Post-translational modification of Rta of Epstein-Barr virus by SUMO-1. J Biol Chem. 2004 Sep 10; 279(37):38803–12. https://doi.org/10.1074/jbc.M405470200 PMID: 15229220

68. Chang LK, Liu ST, Kuo CW, Wang WH, Chuang JY, Bianchi E, et al. Enhancement of transactivation activity of Rta of Epstein-Barr virus by RanBPM. J Mol Biol. 2008 May 30; 379(2):231–42. https://doi.org/10.1016/j.jmb.2008.04.011 PMID: 18455188

69. Adamson AL. Effects of SUMO-1 upon Epstein-Barr virus BZLF1 function and BMRF1 expression. Biochem Biophys Res Commun. 2005 Oct 14; 336(1):22–8. https://doi.org/10.1016/j.bbrc.2005.08.036 PMID: 16112644

70. Enserink JM. Sumo and the cellular stress response. Cell Div. 2015; 10:4. https://doi.org/10.1186/s13008-015-0010-1 PMID: 26101541

71. Donaghy G, Jupp R. Characterization of the Epstein-Barr virus proteinase and comparison with the human cytomegalovirus proteinase. J Virol. 1995 Feb; 69(2):1265–70. PMID: 7815503

72. Liu X, Cohen JI. Epstein-Barr Virus (EBV) Tegument Protein BGLF2 Promotes EBV Reactivation through Activation of the p38 Mitogen-Activated Protein Kinase. J Virol. 2015 Nov 11; 90(2):1129–38. https://doi.org/10.1128/JVI.01410-15 PMID: 26559845

73. Konishi N, Narita Y, Hijioka F, Masud H, Sato Y, Kimura H, et al. BGLF2 Increases Infectivity of Epstein-Barr Virus by Activating AP-1 upon De Novo Infection. mSphere. 2018 Apr 25; 3(2).

74. Tsurumi T, Daikoku T, Kurachi R, Nishiyama Y. Functional interaction between Epstein-Barr virus DNA polymerase catalytic subunit and its accessory subunit in vitro. J Virol. 1993 Dec; 67(12):7648–53. PMID: 8230484

75. Zhang Q, Holley-Guthrie E, Ge JQ, Dorsky D, Kenney S. The Epstein-Barr virus (EBV) DNA polymerase accessory protein, BMRF1, activates the essential downstream component of the EBV oriLyt. Virology. 1997 Mar 31; 230(1):22–34. https://doi.org/10.1006/viro.1997.8470 PMID: 9126259

76. Holley-Guthrie EA, Seaman WT, Bhende P, Merchant JL, Kenney SC. The Epstein-Barr virus protein BMRF1 activates gastrin transcription. J Virol. 2005 Jan; 79(2):745–55. https://doi.org/10.1128/JVI.79.2.745-755.2005 PMID: 15613302

77. Su MT, Wang YT, Chen YJ, Lin SF, Tsai CH, Chen MR. The SWI/SNF Chromatin Regulator BRG1 Modulates the Transcriptional Regulatory Activity of the Epstein-Barr Virus DNA Polymerase Processivity Factor BMRF1. J Virol. 2017 May 01; 91(9).
78. Hiriart E, Bardouille L, Manet E, Gruffat H, Penin F, Montserret R, et al. A region of the Epstein-Barr virus (EBV) mRNA export factor EB2 containing an arginine-rich motif mediates direct binding to RNA. J Biol Chem. 2003 Sep 26; 278(39):37790–8. https://doi.org/10.1074/jbc.M305925200 PMID: 12857728

79. Gillis PA, Okagaki LH, Rice SA. Herpes simplex virus type 1 ICP27 induces p38 mitogen-activated protein kinase signaling and apoptosis in HeLa cells. J Virol. 2009 Feb; 83(4):1767–77. https://doi.org/10.1128/JVI.01944-08 PMID: 19073744

80. Hargett D, Rice S, Bachenheimer SL. Herpes simplex virus type 1 ICP27-dependent activation of NF-kappaB. J Virol. 2006 Nov; 80(21):10565–78. https://doi.org/10.1128/JVI.01119-06 PMID: 16928747

81. Christensen MH, Jensen SB, Miettinen JJ, Luecke S, Prabakaran T, Reinert LS, et al. HSV-1 ICP27 targets the TBK1-activated STING signalosome to inhibit virus-induced type I IFN expression. Embo J. 2016 Jul 01; 35(13):1385–99. https://doi.org/10.15252/embj.201593458 PMID: 27234299

82. Hendriks IA, D’Souza RC, Yang B, Verlaan-de Vries M, Mann M, Vertegaal AC. Uncovering global SUMOylation signaling networks in a site-specific manner. Nat Struct Mol Biol. 2016 Jul 01; 35(13):1385–99. https://doi.org/10.1038/embj.201593458 PMID: 27234299

83. Blomster HA, Hietakangas V, Wu J, Kouvonen P, Hautanien S, Sistonen L. Novel proteomics strategy brings insight into the prevalence of SUMO-2 target sites. Mol Cell Proteomics. 2009 Jun; 8 (6):1382–90. https://doi.org/10.1074/mcp.M800551-MCP200 PMID: 19240082

84. Richard P, Vethanathan V, Manley JL. Roles of Sumoylation in mRNA Processing and Metabolism. Adv Exp Med Biol. 2017; 963:15–33. https://doi.org/10.1007/978-3-319-50044-7_2 PMID: 28197904

85. Forler D, Rabut G, Ciccarelli FD, Herold A, Kocher T, Niggeweg R, et al. RanBP2/Nup358 provides a major binding site for NXF1-p15 dimers at the nuclear pore complex and functions in nuclear mRNA export. Mol Cell Biol. 2004 Feb; 24(3):1155–67. https://doi.org/10.1128/MCB.24.3.1155-1167.2004 PMID: 14729961

86. Mahadevan K, Zhang H, Akef A, Cui XA, Guarroussov S, Cenik C, et al. RanBP2/Nup358 potentiates the translation of a subset of mRNAs encoding secretory proteins. PLoS Biol. 2013; 11(4):e1001545. https://doi.org/10.1371/journal.pbio.1001545 PMID: 23630457

87. Cappadocia L, Pichler A, Lima CD. Structural basis for catalytic activation by the human ZNF451 SUMO E3 ligase. Nat Struct Mol Biol. 2015 Dec; 22(12):968–75. https://doi.org/10.1038/nsmb.3116 PMID: 26524494

88. Eisenhardt N, Chaugule VK, Koidl S, Droescher M, Dogan E, Rettich J, et al. A new vertebrate SUMO enzyme family reveals insights into SUMO-chain assembly. Nat Struct Mol Biol. 2015 Dec; 22 (12):959–67. https://doi.org/10.1038/nsmb.3114 PMID: 26524493

89. Pichler A, Fatouros C, Lee H, Eisenhardt N. SUMO conjugation—a mechanistic view. Biomol Concepts. 2017 Mar 1; 8(1):13–36. https://doi.org/10.1515/bmc-2016-0030 PMID: 28284030

90. Pichler A, Knipscheer P, Saitoh H, Sixma TK, Melchior F. The RanBP2 SUMO E3 ligase is neither HECT- nor RING-type. Nat Struct Mol Biol. 2004 Oct; 11(10):984–91. https://doi.org/10.1038/nsmb834 PMID: 15378033

91. Karvonen U, Jaaskaalien T, Rytinki M, Kaikkonen S, Palvimo JJ. ZNF451 is a novel PML body- and SUMO-associated transcriptional coregulator. J Mol Biol. 2008 Oct 10; 382(3):585–600. https://doi.org/10.1016/j.jmb.2008.07.016 PMID: 18656483

92. Patel V, Dahiroth SL, Rajakannan V, Ho HT, Cornvik T, Nordlund P. Structure of the C-Terminal Domain of the Multifunctional ICP27 Protein from Herpes Simplex Virus 1. J Virol. 2015 Sep; 89 (17):8828–39. https://doi.org/10.1128/JVI.00441-15 PMID: 26085142

93. Tunnicliffe RB, Schacht M, Levy C, Jowitt TA, Sandri-Goldin RM, Golovanov AP. The structure of the folded domain from the signature multifunctional protein ICP27 from herpes simplex virus-1 reveals an intertwined dimer. Sci Rep. 2015 Jun 11; 5:11234. https://doi.org/10.1038/srep11234 PMID: 26062451

94. Stehmeier P, Muller S. Regulation of p53 family members by the ubiquitin-like SUMO system. DNA Repair (Amst). 2009 Apr 5; 8(4):491–8.

95. Gostissa M, Hengstermann A, Fogal V, Sandy P, Schwarz SE, Scheffner M, et al. Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1. Embo J. 1999 Nov 15; 18(22):6462–71. https://doi.org/10.1093/emboj/18.22.6462 PMID: 10562558

96. Rodriguez MS, Desterro JM, Lain S, Midgley CA, Lane DP, Hay RT. SUMO-1 modification activates the transcriptional response of p53. Embo J. 1999 Nov 15; 18(22):6455–61. https://doi.org/10.1093/emboj/18.22.6455 PMID: 10562557

97. Stindt MH, Carter S, Vigneron AM, Ryan KM, Vousden KH. MDM2 promotes SUMO-2/3 modification of p53 to modulate transcriptional activity. Cell Cycle. 2011 Sep 15; 10(18):3176–88. https://doi.org/10.4161/cc.10.18.17436 PMID: 21900752
98. Yang WS, Hsu HW, Campbell M, Cheng CY, Chang PC. K-bZIP Mediated SUMO-2/3 Specific Modification on the KSHV Genome Negatively Regulates Lytic Gene Expression and Viral Reactivation. PLoS Pathog. 2015 Jul; 11(7):e1005051. https://doi.org/10.1371/journal.ppat.1005051 PMID: 26197391

99. Wang J, Guo Y, Wang X, Zhao R, Wang Y. Modulation of global SUMOylation by Kaposi’s sarcoma-associated herpesvirus and its effects on viral gene expression. J Med Virol. 2017 Nov; 89(11):2011–9. https://doi.org/10.1002/jmv.24882 PMID: 28639696

100. Everly DN Jr., Mainou BA, Raab-Traub N. Induction of Id1 and Id3 by latent membrane protein 1 of Epstein-Barr virus and regulation of p27Kip and cyclin-dependent kinase 2 in rodent fibroblast transformation. J Virol. 2004 Dec; 78(24):13470–8. https://doi.org/10.1128/JVI.78.24.13470-13478.2004 PMID: 15564458

101. Everett RD, Meredith M, Orr A. The ability of herpes simplex virus type 1 immediate-early protein Vmw110 to bind to a ubiquitin-specific protease contributes to its roles in the activation of gene expression and stimulation of virus replication. J Virol. 1999 Jan; 73(1):417–26. PMID: 9847347

102. Desterro JM, Rodriguez MS, Hay RT. SUMO-1 modification of IkappaBalpha inhibits NF-kappaB activation. Mol Cell. 1998 Aug; 2(2):233–9. PMID: 9734360

103. Tatham MH, Jaffray E, Vaughan OA, Desterro JM, Botting CH, Naismith JH, et al. Polymeric chains of SUMO-2 and SUMO-3 are conjugated to protein substrates by SAE1/SAE2 and Ubc9. J Biol Chem. 2001 Sep 21; 276(38):35368–74. https://doi.org/10.1074/jbc.M104214200 PMID: 11451954

104. Davis ZH, Verschuereen E, Jang GM, Kieffer K, Johnson JR, Park J, et al. Global mapping of herpesvirus-host protein complexes reveals a transcription strategy for late genes. Mol Cell. 2015 Jan 22; 57(2):349–60. https://doi.org/10.1016/j.molcel.2014.11.026 PMID: 25544563

105. Li W, You L, Cooper J, Schiavon G, Pepe-Caprio A, Zhou L, et al. Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus. Cell. 2010 Feb 19; 140(4):477–90. https://doi.org/10.1016/j.cell.2010.01.029 PMID: 20178741

106. Tatham MH, Rodriguez MS, Xirodimas DP, Hay RT. Detection of protein SUMOylation in vivo. Nat Protoc. 2009; 4(9):1363–71. https://doi.org/10.1038/nprot.2009.128 PMID: 19730420

107. Sun Y, Hegamyer G, Cheng YJ, Hildesheim A, Chen JY, Chen IH, et al. An infrequent point mutation of the p53 gene in human nasopharyngeal carcinoma. Proc Natl Acad Sci U S A. 1992 Jul 15; 89(14):6516–20. PMID: 1631151

108. Borza CM, Hutt-Fletcher LM. Alternate replication in B cells and epithelial cells switches tropism of Epstein-Barr virus. Nat Med. 2002 Jun; 8(6):594–9. https://doi.org/10.1038/nm0602-594 PMID: 12042810

109. Yin Y, Seifert A, Chua JS, Maure JF, Golebiowski F, Hay RT. SUMO-targeted ubiquitin E3 ligase RNF4 is required for the response of human cells to DNA damage. Genes Dev. 2012 Jun 1; 26(11):1196–208. https://doi.org/10.1101/gad.189274.112 PMID: 22661230